Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CP-506 |
Synonyms | |
Therapy Description |
CP-506 is a DNA alkylating hypoxia-activated prodrug, which potentially induces cytotoxicity in tumor cells under hypoxic conditions and inhibits tumor growth (PMID: 34625504). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CP-506 | CP 506|CP506 | Chemotherapy - Alkylating 18 | CP-506 is a DNA alkylating hypoxia-activated prodrug, which potentially induces cytotoxicity in tumor cells under hypoxic conditions and inhibits tumor growth (PMID: 34625504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04954599 | Phase Ib/II | CP-506 CP-506 + Ipilimumab Carboplatin + CP-506 Cemiplimab + CP-506 CP-506 + Durvalumab CP-506 + Pembrolizumab CP-506 + Nivolumab Avelumab + CP-506 Atezolizumab + CP-506 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | Recruiting | NLD | BEL | 0 |